Mitochondrial dysfunction-associated microbiota establishes a transmissible refractory response to anti-TNF therapy during ulcerative colitis
A Peña-Cearra, J Castelo, JL Lavín… - Gut …, 2023 - Taylor & Francis
Anti-TNF therapy can induce and maintain a remission status during intestinal bowel
disease. However, up to 30% of patients do not respond to this therapy by mechanisms that …
disease. However, up to 30% of patients do not respond to this therapy by mechanisms that …
Mitochondrial dysfunction-associated microbiota establishes a transmissible refractory response to anti-TNF therapy during ulcerative colitis
A Peña-Cearra, J Castelo, JL Lavín… - Gut …, 2023 - pubmed.ncbi.nlm.nih.gov
Anti-TNF therapy can induce and maintain a remission status during intestinal bowel
disease. However, up to 30% of patients do not respond to this therapy by mechanisms that …
disease. However, up to 30% of patients do not respond to this therapy by mechanisms that …
Mitochondrial dysfunction-associated microbiota establishes a transmissible refractory response to anti-TNF therapy during ulcerative colitis.
A Peña-Cearra, J Castelo, JL Lavín… - Gut …, 2023 - europepmc.org
Anti-TNF therapy can induce and maintain a remission status during intestinal bowel
disease. However, up to 30% of patients do not respond to this therapy by mechanisms that …
disease. However, up to 30% of patients do not respond to this therapy by mechanisms that …
[HTML][HTML] Mitochondrial dysfunction-associated microbiota establishes a transmissible refractory response to anti-TNF therapy during ulcerative colitis
A Peña-Cearra, J Castelo, JL Lavín… - Gut …, 2023 - ncbi.nlm.nih.gov
Anti-TNF therapy can induce and maintain a remission status during intestinal bowel
disease. However, up to 30% of patients do not respond to this therapy by mechanisms that …
disease. However, up to 30% of patients do not respond to this therapy by mechanisms that …
Mitochondrial dysfunction-associated microbiota establishes a transmissible refractory response to anti-TNF therapy during ulcerative colitis.
A Peña-Cearra, J Castelo, JL Lavín… - Gut …, 2023 - europepmc.org
Anti-TNF therapy can induce and maintain a remission status during intestinal bowel
disease. However, up to 30% of patients do not respond to this therapy by mechanisms that …
disease. However, up to 30% of patients do not respond to this therapy by mechanisms that …